ABSTRACT
Background: Ending the tuberculosis (TB) epidemic by 2030 is among the health targets of the sustainable development goals. Side effects to anti-TB drugs are common and may lead to reduced compliance to treatment. These adverse effects must be recognized early to reduce associated morbidity and mortality. Objective of this study was to determine the adverse drug reactions (ADR) to anti-tubercular therapy among patients visiting directly observed treatment, short-course (DOTS) centre MIMS, Mandya.Methods: A cross sectional study was conducted at DOTS Centre MIMS, Mandya. TB patients registered at DOTS Centre during the year 2018 were selected for the study. Verbal informed consent was taken from the TB patients and interviewed using pretested semi-structured questionnaire. Data analysis was done using descriptive statistics and chi square test.Results: Among the study population (n=90), 67 (74.4%) experienced ADR among which 47.7% took treatment for ADR and the remaining 52.3% patients were given reassurance. In this study, gastrointestinal manifestations (42.3%) were the most common adverse drug reaction (ADR). Of the TB patients who experienced ADR, 9.0% of them had interrupted ATT, however they completed full course of ATT.Conclusions: A considerable number of TB patients taking ATT experience ADRs and some of them may have to interrupt treatment. However, they need to be counselled or supervised with caution to complete their course of treatment to reduce the chances of treatment default and also reduce the occurrence of drug resistance.
ABSTRACT
Background: In the act of medical practice, referral is the transfer of a patient’s care from one physician or clinician to another. Appropriate referral is an integral part of a complete quality health care management. At present, patients can visit any level of health care irrespective of severity of their health condition and most of the burden of these patients is on tertiary centers. This study was done to describe the Referral Pattern of Patients Coming to Mandya Institute of Medical Sciences, Mandya.Methods: It was a cross sectional study conducted from October 2017 to November 2017 with sample size of 400, p=50%. Sampling technique used was convenient sampling and data was collected by interview using the semistructured questionnaire.Results: Among the study population 197 (49.3%) were males and 203 (50.7%) were females, 392 (82.3%) had BPL card. Mean distance travelled by them to MIMS was 17.7±14.8 km. Medicine department n=80 (20%) followed by ophthalmology department n=64 (16%) were the most frequently visited departments. Mean distance to the nearest health center from their place of residence was 3.2%±2.9 km. 148 (37.0%) visited the health center near their place of residence before coming to MIMS and 253 (63.0%) did not visit.Conclusions: Most of the patients visited tertiary healthcare center (MIMS) without visiting health center near to them, though the distance is more and availability of specialists and low cost of treatment were the main reasons for visiting MIMS.
ABSTRACT
Background: WHO guidelines recommend for treating Cat III animal bite victims with local infiltration of Equine Rabies Immunoglobulin (ERIG) into and around animal bite wounds followed by anti-rabies vaccine (ARV).The main reason for non-use of ERIGs by medical profession is the fear of anaphylaxis and laborious process. The present study was taken up with the objectives to assess the clinical safety of a new ERIG, describe sociodemographic profile of ERIG recipients and compliance to Intra Dermal Rabies Vaccine (IDRV), who reported to Anti Rabies Clinic (ARC) of Mandya Institute of Medical Sciences (MIMS), Mandya.Methods: Descriptive study at ARC, MIMS, Mandya for a period of one year. The data was collected using structured questionnaire. The data was entered into Microsoft excel and results were expressed using descriptive statistics.Results: The study revealed that cat III animal bite victims were 3400 (56.3%), of these only 545 (16.0%) opted for the new ERIG. Skin Sensitivity Test (SST) showed positive results in 17 (3.1%) cases. Among the ERIG recipients 28 (5.1%) had mild adverse reaction to ERIG. The compliance rate was 49.2% for all 4 doses of IDRV.Conclusions: 3.1% showed positive result to SST. 5.1% had mild adverse reaction to ERIG.